MEI Pharma, Inc. (MEIP)

Market Cap	18.66M
Revenue (ttm)	66.75M
Net Income (ttm)	26.16M
Shares Out	6.66M
EPS (ttm)	3.92
PE Ratio	0.71
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,603
Open	2.840
Previous Close	2.850
Day's Range	2.780 - 2.855
52-Week Range	2.730 - 7.870
Beta	0.68
Analysts	Hold
Price Target	7.00 (+150.0%)
Earnings Date	May 9, 2024

About MEIP

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2003
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: MEIP

Financial Performance

In 2023, MEI Pharma's revenue was $48.82 million, an increase of 19.95% compared to the previous year's $40.70 million. Losses were -$31.84 million, -41.53% less than in 2022.

Analyst Forecast

According to one analyst, the rating for MEIP stock is "Hold" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(150.00% upside)

Analyst Consensus: Hold